Navigation Links
Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
Date:9/30/2008

PASADENA, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Jacobs Engineering Group Inc. (NYSE: JEC) announced today that it received a contract from Gedeon Richter (BSE: GDRB) to provide engineering, procurement, and construction management services and validation assistance for a grassroots, multi-purpose biotechnology research & development and manufacturing facility in Debrecen, Hungary.

Officials did not disclose contract details but noted they would execute the work from their office in Milan, Italy.

Gedeon Richter, headquartered in Budapest, Hungary, is one of the largest multinational pharmaceutical companies in Central Eastern Europe and the Commonwealth of Independent States. It has a growing presence through commercial subsidiaries in key European Union countries, Asia, and the United States.

In making the announcement, Jacobs Group Vice President Robert Matha said "We are eager to help Gedeon Richter with this important project, which strengthens its commitment to biotechnology. In supporting the company's strategic goal of establishing a strong biopharma line, we also help Gedeon Richter to expand its worldwide portfolio of high value products."

Jacobs, with over 56,000 employees and revenues exceeding $10.0 billion, provides technical, professional, and construction services globally.

Any statements made in this release that are not based on historical fact are forward-looking statements. Although such statements are based on management's current estimates and expectations, and currently available competitive, financial, and economic data, forward-looking statements are inherently uncertain. We, therefore, caution the reader that there are a variety of factors that could cause business conditions and results to differ materially from what is contained in our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2007 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We also caution the readers of this release that we do not undertake to update any forward-looking statements made herein.

For additional information contact:

Michelle Jones

626.578.6968

(Logo: http://www.newscom.com/cgi-bin/prnh/20051021/LAJACOBSEGLOGO)


'/>"/>
SOURCE Jacobs Engineering Group Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
2. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
5. Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets
6. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
7. AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM)
8. PLC Systems Receives Delisting Notice From American Stock Exchange
9. Nephros Receives Non-Compliance Notification from AMEX
10. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
11. Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/9/2016)... Finland , June 9, 2016 ... National Police deploy Teleste,s video security solution to ensure the ... France during the major tournament ... data communications systems and services, announced today that its video ... Prefecture to back up public safety across the ...
Breaking Biology News(10 mins):